Case report: the dissociated response and clinical benefit of primary leiomyosarcoma of the bone treated with penpulimab plus lenvatinib after failed multi-line therapy

Overview of attention for article published in Frontiers in Pharmacology, November 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter: 2 X users

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 5,892 followers.

Case report: the dissociated response and clinical benefit of primary leiomyosarcoma of the bone treated with penpulimab plus lenvatinib after failed multi-line therapy https://t.co/EZB7nuAFXY #sarcoma #leiomyosarcoma

29 Nov 2023

Reply Repost Favourite

New Research: Case report: the dissociated response and clinical benefit of primary leiomyosarcoma of the bone treated with penpulimab plus lenvatinib after failed multi-line therapy https://t.co/uvMGpnrEw0 #pharmacology

09 Nov 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.